Precision BioSciences, Inc. (DTIL)

Precision BioSciences, Inc. (DTIL) Healthcare & Pipeline Overview

Precision BioSciences, Inc. is a clinical-stage biotechnology firm specializing in gene editing with its ARCUS platform and allogeneic CAR T therapies. The company targets genetic disorders and cancers, positioning itself in the competitive landscape of gene therapy and immunotherapy with strategic partnerships for expanded development.

What Is the Investment Thesis for DTIL?

Precision BioSciences presents a high-risk, high-reward investment profile characteristic of clinical-stage biotechnology companies. The ARCUS platform's potential for precise gene editing offers a competitive edge in addressing genetic disorders and cancers. Key value drivers include the advancement of PBCAR0191 through clinical trials, with Phase 1/2a data expected to provide crucial insights into efficacy and safety. The company's partnerships with Servier, Tiziana, and iECURE represent potential revenue streams and expanded therapeutic applications. However, the company's negative profit margin of -98.7% highlights its reliance on external funding and successful clinical outcomes. Upcoming data readouts and regulatory milestones will be critical catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the gene editing and CAR T therapy spaces.

Based on FMP financials and quantitative analysis

DTIL Key Highlights

• Market Cap of $104.93M reflects its position as a clinical-stage biotech company with potential for growth pending clinical trial outcomes.
• Gross Margin of 97.0% indicates strong potential profitability for its therapies, assuming successful commercialization.
• Profit Margin of -98.7% highlights the significant R&D expenses and lack of product revenue typical of companies in this stage.
• Development and commercial license agreement with Les Laboratoires Servier provides a potential revenue stream and validation of its technology.
• Phase 1/2a clinical trial of PBCAR0191 represents a critical milestone in the development of its allogeneic CAR T therapies.

Who Are DTIL's Competitors?

DTIL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DTIL's Key Strengths?

• Proprietary ARCUS gene editing platform.
• Allogeneic CAR T therapy development.
• Strategic partnerships with established companies.
• Clinical-stage pipeline with multiple candidates.

What Are DTIL's Weaknesses?

• High operating expenses and negative profit margin.
• Reliance on external funding and partnerships.
• Clinical trial risks and regulatory hurdles.
• Competition from larger, more established companies.

What Could Drive DTIL Stock Higher?

• Data readouts from Phase 1/2a clinical trial of PBCAR0191 in R/R NHL and B-ALL.
• Regulatory milestones for allogeneic CAR T therapy candidates.
• Progress in strategic partnerships with Les Laboratoires Servier, Tiziana Life Sciences, and iECURE.
• Advancement of ARCUS platform for in vivo gene editing applications.

What Are the Key Risks for DTIL?

• Financial-distress signal — its Altman Z-Score of -4.25 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-81.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or setbacks for key pipeline candidates.
• Regulatory delays or rejection of therapeutic products.
• Competition from other gene editing and CAR T companies.
• Market adoption and reimbursement challenges for novel therapies.
• Dependence on external funding and partnerships.

What Are the Growth Opportunities for DTIL?

• Advancement of PBCAR0191 through Clinical Trials: The successful completion of Phase 1/2a clinical trials for PBCAR0191 in R/R NHL and B-ALL represents a significant growth opportunity. Positive data could lead to accelerated regulatory pathways and potential commercialization, addressing a market with substantial unmet needs. The NHL market alone is projected to reach $27.9 billion by 2029, offering a considerable revenue opportunity for Precision BioSciences.
• Expansion of Allogeneic CAR T Pipeline: Developing and advancing additional allogeneic CAR T candidates, such as PBCAR19B and PBCAR269A, can broaden the company's therapeutic reach and address a wider range of hematological malignancies. The CAR T therapy market is expected to continue its rapid growth, providing a favorable environment for Precision BioSciences' pipeline expansion. Success in these areas would significantly increase the company's market capitalization.
• Leveraging the ARCUS Platform for In Vivo Gene Editing: Utilizing the ARCUS platform for in vivo gene editing therapies offers the potential to target genetic disorders directly within the patient's body. This approach could revolutionize the treatment of various genetic diseases, with a market size estimated to reach $14 billion by 2030. Precision BioSciences' expertise in gene editing positions it favorably to capitalize on this emerging market.
• Strategic Partnerships and Collaborations: Continuing to establish strategic partnerships and collaborations with pharmaceutical companies and research institutions can accelerate the development and commercialization of Precision BioSciences' therapies. The agreement with Les Laboratoires Servier exemplifies this approach, providing access to resources and expertise for expanding the CAR T pipeline. Further collaborations can unlock new therapeutic areas and revenue streams.
• Addressing Solid Tumors with Novel CAR T Approaches: Expanding the application of CAR T therapies to solid tumors represents a significant growth opportunity, as solid tumors pose a greater challenge due to their complex microenvironment. Precision BioSciences' research into novel CAR T designs and strategies to overcome these challenges could position it as a leader in this area. The solid tumor market represents a substantial untapped opportunity for CAR T therapies.

What Opportunities Does DTIL Have?

• Advancement of PBCAR0191 through clinical trials.
• Expansion of allogeneic CAR T pipeline.
• Leveraging ARCUS for in vivo gene editing.
• Addressing solid tumors with novel CAR T approaches.

What Threats Does DTIL Face?

• Clinical trial failures and setbacks.
• Regulatory delays and rejection.
• Competition from other gene editing and CAR T companies.
• Market adoption and reimbursement challenges.

What Are DTIL's Competitive Advantages?

• ARCUS Platform: The ARCUS genome editing platform provides a unique and versatile approach to gene editing, offering potential advantages in terms of specificity and efficiency.
• Allogeneic CAR T Technology: The allogeneic CAR T approach aims to overcome limitations of autologous CAR T therapies, such as manufacturing complexities and patient-specific variability.
• Strategic Partnerships: Collaborations with Les Laboratoires Servier, Tiziana Life Sciences, and iECURE provide access to resources, expertise, and expanded therapeutic applications.
• Clinical Stage Pipeline: The presence of clinical-stage assets, such as PBCAR0191, provides a competitive advantage over companies with earlier-stage programs.

What Does DTIL Do?

Precision BioSciences, Inc., founded in 2006 and headquartered in Durham, North Carolina, is a clinical-stage biotechnology company focused on advancing gene editing therapies. The company's core technology is the ARCUS genome editing platform, designed to provide a precise and versatile approach to gene editing for therapeutic applications. Precision BioSciences develops both in vivo gene editing therapies, where the editing occurs directly within the patient's body, and ex vivo allogeneic CAR T therapies, which involve modifying immune cells outside the body before re-infusion. The company's pipeline includes several allogeneic CAR T immunotherapy candidates, such as PBCAR0191, currently in Phase 1/2a clinical trials for adult patients with relapsed or refractory non-Hodgkin lymphoma (R/R NHL) or B-cell precursor acute lymphoblastic leukemia (B-ALL). Other candidates include PBCAR19B, an anti-CD19 CAR T therapy, and PBCAR269A, targeting BCMA for relapsed or refractory multiple myeloma. Precision BioSciences has established strategic collaborations to expand its therapeutic reach, including agreements with Les Laboratoires Servier for allogeneic CAR T cell therapies, Tiziana Life Sciences for novel lymphodepletion strategies, and iECURE, Inc. for ARCUS-based gene editing therapies. These partnerships underscore the company's commitment to innovation and addressing unmet medical needs in oncology and genetic disorders.

What Products and Services Does DTIL Offer?

• Develops in vivo gene editing therapies using the ARCUS platform.
• Creates ex vivo allogeneic CAR T therapies for cancer treatment.
• Conducts clinical trials for its CAR T immunotherapy candidates.
• Partners with other companies to expand its therapeutic reach.
• Targets genetic disorders and hematological malignancies.
• Utilizes its ARCUS platform for precise genome editing.

How Does DTIL Make Money?

• Develops and out-licenses gene editing technologies and CAR T therapies.
• Generates revenue through research and development collaborations.
• Aims to commercialize its own therapeutic products upon regulatory approval.
• Focuses on partnerships to expand its pipeline and market reach.

What Industry Does DTIL Operate In?

Precision BioSciences operates within the rapidly evolving biotechnology industry, specifically in the gene editing and CAR T therapy sectors. The market for gene editing technologies is projected to reach billions of dollars by the late 2020s, driven by advancements in CRISPR, ARCUS, and other platforms. The competitive landscape includes companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA), which are also developing gene editing therapies. Precision BioSciences differentiates itself with its ARCUS platform, which offers unique specificity and versatility. The CAR T therapy market is also experiencing significant growth, with increasing adoption for hematological malignancies and expanding research into solid tumors. Precision BioSciences' allogeneic approach aims to overcome limitations of autologous CAR T therapies, such as manufacturing complexities and patient-specific variability.

Who Are DTIL's Key Customers?

• Patients with genetic disorders.
• Patients with relapsed or refractory hematological malignancies.
• Pharmaceutical companies seeking gene editing technologies.
• Research institutions collaborating on therapeutic development.

ROE -81%Key Financial Metrics

Return on equity for Precision BioSciences, Inc. stands at -81.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -71.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -53.8%, the inverse of the P/E and a quick read on earnings relative to price.

Precision BioSciences, Inc. (DTIL) Valuation Context

Valued at $104.93M, DTIL is classified as a micro-cap stock. Relative to its peer group, DTIL's quantitative score of 16/100 is below the peer average of 67/100.

Company Profile

Precision BioSciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Durham, US. The company is led by CEO Juli Blanche. DTIL has traded publicly since 2019.

F-Score 1/9Financial Health

Precision BioSciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.25 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Precision BioSciences, Inc. revenue of about $18.6M for fiscal 2026, with EPS near $-2.81. The estimate reflects 3 contributing analysts.

DTIL Financials

DTIL Latest News

DTIL Analyst Consensus

DTIL MoonshotScore

Precision BioSciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources